Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 42, 2010, Pages 18202-18207

  Das, Anindita ^a   Durrant, David ^a   Mitchell, Clint ^b   Mayton, Eric ^a   Hoke, Nicholas N ^a   Salloum, Fadi N ^a   Park, Margaret A ^b   Qureshi, Ian ^a   Lee, Ray ^b   Dent, Paul ^b   Kukreja, Rakesh C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Phosphodiesterase 5; Reactive oxygen species

Indexed keywords

CASPASE 3; CASPASE 9; DOXORUBICIN; PHOSPHODIESTERASE V; PROTEIN BAD; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; HEART LEFT VENTRICLE DYSFUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CASPASE 3; CASPASE 9; DOXORUBICIN; DRUG SYNERGISM; ECHOCARDIOGRAPHY, DOPPLER; HEART; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PIPERAZINES; PROSTATIC NEOPLASMS; PURINES; REACTIVE OXYGEN SPECIES; SULFONES;

MUS;

EID: 78149278340     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1006965107     Document Type: Article

References (41)

1. Leonetti C, et al. (2007) Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer. Prostate 67:1475-1485.
2. Singal PK, Li T, Kumar D, Danelisen I, Iliskovic N (2000) Adriamycin-induced heart failure: Mechanism and modulation. Mol Cell Biochem 207:77-86.
3. Rivera E (2003) Liposomal anthracyclines in metastatic breast cancer: Clinical update. Oncologist 8(Suppl 2):3-9.
4. Shen F, et al. (2008) Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 324: 95-102.
5. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use. Pharmacol Rev 58:488-520.
6. Das A, Ockaili R, Salloum F, Kukreja RC (2004) Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am J Physiol Heart Circ Physiol 286: H1455-H1460.
7. Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280:12944-12955.
8. Ockaili R, Salloum F, Hawkins J, Kukreja RC (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283:H1263-H1269.
9. Salloum F, Yin C, Xi L, Kukreja RC (2003) Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ Res 92:595-597.
10. Salloum FN, Ockaili RA, Wittkamp M, Marwaha VR, Kukreja RC (2006) Vardenafil: A novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits. J Mol Cell Cardiol 40:405-411.
11. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111:1601-1610.
12. Salloum FN, et al. (2008) Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 294: H1398-H1406.
13. Das A, Xi L, Kukreja RC (2008) Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283:29572-29585.
14. Das A, Salloum FN, Xi L, Rao YJ, Kukreja RC (2009) ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice. Am J Physiol Heart Circ Physiol 296:H1236-H1243.
15. Piazza GA, et al. (2001) Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 61:3961-3968.
16. Pusztai L, et al. (2003) Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer. J Clin Oncol 21:3454-3461. (Pubitemid 46594078)
17. Whitehead CM, et al. (2003) Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2:479-488.
18. Sarfati M, et al. (2003) Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 101:265-269.
19. Zhu B, Vemavarapu L, Thompson WJ, Strada SJ (2005) Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 94:336-350. (Pubitemid 41420312)
20. Li H, et al. (2002) Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 64:1325-1336.
21. Goluboff ET, et al. (1999) Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 53: 440-445.
22. Lim JT, et al. (1999) Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 58:1097-1107.
23. Lim JT, Piazza GA, Pamukcu R, Thompson WJ, Weinstein IB (2003) Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clin Cancer Res 9:4972-4982.
24. Narayanan BA, et al. (2007) Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: In vivo evidence. Clin Cancer Res 13:5965-5973.
25. Mizutani H, Tada-Oikawa S, Hiraku Y, Kojima M, Kawanishi S (2005) Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 76:1439-1453.
26. Tsang WP, Chau SP, Kong SK, Fung KP, Kwok TT (2003) Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 73:2047-2058.
27. Wang HG, et al. (1999) Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 284:339-343.
28. Pinto AC, Moreira JN, Simões S (2009) Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner. Cancer Chemother Pharmacol 64:445-454.
29. Rambhatla A, Kovanecz I, Ferrini M, Gonzalez-Cadavid NF, Rajfer J (2008) Rationale for phosphodiesterase 5 inhibitor use post-radical prostatectomy: Experimental and clinical review. Int J Impot Res 20:30-34.
30. Mydlo JH, Viterbo R, Crispen P (2005) Use of combined intracorporal injection and a phosphodiesterase-5 inhibitor therapy for men with a suboptimal response to sildenafil and/or vardenafil monotherapy after radical retropubic prostatectomy. BJU Int 95:843-846.
31. Ohebshalom M, Parker M, Guhring P, Mulhall JP (2005) The efficacy of sildenafil citrate following radiation therapy for prostate cancer: Temporal considerations. J Urol 174:258-262, discussion 262.
32. Teloken PE, Ohebshalom M, Mohideen N, Mulhall JP (2007) Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 178:2521-2525.
33. Kukreja RC, et al. (2005) Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications. Vascul Pharmacol 42:219-232.
34. Resnick L, Rabinovitz H, Binninger D, Marchetti M, Weissbach H (2009) Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses. J Drugs Dermatol 8:29-32.
35. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick: Metabolism and tumor cell growth. Curr Opin Genet Dev 18:54-61. (Pubitemid 351694453)
36. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033.
37. Moench I, Prentice H, Rickaway Z, Weissbach H (2009) Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms. Proc Natl Acad Sci USA 106:19611-19616.
38. Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6:513-519.
39. Kelly MM, Hoel BD, Voelkel-Johnson C (2002) Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 1:520-527.
40. Bast A, Kaiserová H, den Hartog GJ, Haenen GR, van der Vijgh WJ (2007) Protectors against doxorubicin-induced cardiotoxicity: Flavonoids. Cell Biol Toxicol 23:39-47.
41. Bryant J, et al. (2007) Use of cardiac markers to assess the toxic effects of anthracyclines given to children with cancer: A systematic review. Eur J Cancer 43:1959-1966. (Pubitemid 47299200)